ReviewTranslational research : the journal of laboratory and clinical medicine2012
Biomarkers in inflammatory bowel disease: current practices and recent advances.
Review in Translational research : the journal of laboratory and clinical medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 211 citations in OpenAlex.
- Serological and faecal markers of irritable bowel syndrome: a systematic review and meta-analysis.EBioMedicine · 2026Pooled it
- Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.Health technology assessment (Winchester, England) · 2021Pooled it
- Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.CPT: pharmacometrics & systems pharmacology · 2023Trial
- Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity.Inflammatory bowel diseases · 2015Trial
- Optimising clinical trial design choices in inflammatory bowel disease.BMJ open gastroenterology · 2026Review
- Histologic Activity Modifies the Predictive Value of Systemic Inflammatory Markers in Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2026Article
- Non-Invasive Multimarker Strategy Combining IL-17A, Neutrophil-Albumin Ratio, and Fecal Calprotectin for Accurate Discrimination of IBD from IBS-D.International journal of molecular sciences · 2026Article
- Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026Review
- Ulcerative colitis, but not Crohn's disease, displays demographically and clinically driven mucosal immune heterogeneity: implications for patient stratification.Frontiers in immunology · 2026Article
- Utilization of AhR and GPR35 Receptor Ligands as Superfoods in Cancer Prevention for Individuals with IBD.International journal of molecular sciences · 2025Review
- Network pharmacology analysis and animal experiment validation of inflammation inhibition by Swertiamarin in treating Ulcerative colitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Molecularly Imprinted Polymer Advanced Hydrogels as Tools for Gastrointestinal Diagnostics.Gels (Basel, Switzerland) · 2025Review
- Fecal metabolomics to understand intestinal dysfunction in male dairy beef calves at arrival to the rearing farm.Scientific reports · 2025Article
- Medication-related burden among Iraqi patients with ulcerative colitis: a cross-sectional study.Journal of medicine and life · 2024Article
- Prevalence of spondyloarthritis in inflammatory bowel disease according ASAS and ultrassonography and its correlation with plasma calprotectin.Advances in rheumatology (London, England) · 2024Observational
- The pan-microbiome profiling system Taxa4Meta identifies clinical dysbiotic features and classifies diarrheal disease.The Journal of clinical investigation · 2024Article
- Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice.Gut microbiome (Cambridge, England) · 2024Article
- Causal association of blood cell traits with inflammatory bowel diseases: a Mendelian randomization study.Frontiers in nutrition · 2024Article
- Alteration of stool pH and its association with biomarkers of gut enteropathy among slum-dwelling women of reproductive age in Bangladesh.BMC women's health · 2023Article
- Perceived Use Cases, Barriers, and Requirements for a Smart Health-Tracking Toilet Seat: Qualitative Focus Group Study.JMIR human factors · 2023Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Crohn's disease and ulcerative colitis represent the two main forms of the idiopathic chronic inflammatory bowel diseases (IBD). Currently available blood and stool based biomarkers provide reproducible, quantitative tools that can complement clinical assessment to aid clinicians in IBD diagnosis and management. C-reactive protein and fecal based leukocyte markers can help the clinician distinguish IBD from noninflammatory diarrhea and assess disease activity. The ability to differentiate between forms of IBD and predict risk for disease complications is specific to serologic tests including antibodies against Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic proteins. Advances in genomic, proteomic, and metabolomic array based technologies are facilitating the development of new biomarkers for IBD. The discovery of novel biomarkers, which can correlate with mucosal healing or predict long-term disease course has the potential to significantly improve patient care. This article reviews the uses and limitations of currently available biomarkers and highlights recent advances in IBD biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.